IP Library Granted Patent US 10,227,354
Granted Patent B2
US 10,227,354 · App. 14/132,910 · Granted Mar 12, 2019

Conversion of oxycodone base to oxycodone hydrochloride

Inventors: Zinovy Itov (Cody, WY); Vladimir F. Kuznetsov (Cody, WY); Iouri Voitsekhovski (Cody, WY)
Assignee: Cody Laboratories, Inc.
C07D489/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,227,354
App. No.
14/132,910
Granted
Mar 12, 2019
Kind
B2
Abstract

Synthetic methods are provided for preparation of oxycodone and salts thereof with an improved impurity profile. Thebaine is converted to 14-hydroxycodeinone sulfate intermediate to minimize a 7,8-dihydro-8,14-dihydroxycodeinone impurity. Efficient methods for conversion of oxycodone base to oxycodone hydrochloride are provided to minimize 14-hydroxycodeinone impurity in the final product.

Claims (33)

1. A method for preparation of oxycodone hydrochloride from oxycodone base comprising:

dissolving oxycodone base in an aqueous organic acid solution comprised of water and an organic carboxylic acid, wherein the organic carboxylic acid is acetic acid, to form an oxycodone organic acid salt,

wherein the dissolving is performed at a temperature within a range of from 0° C. to 50° C.; and

adding hydrochloric acid or ammonium chloride to the oxycodone organic acid salt to form oxycodone hydrochloride.

2. The method of claim 1 , wherein the dissolving comprises complete or partial dissolution of the oxycodone base in the aqueous organic acid solution.

3. The method of claim 1 further comprising

crystallizing the oxycodone hydrochloride by adding water and/or one or more water miscible organic solvents to the oxycodone hydrochloride to form purified oxycodone hydrochloride.

4. The method of claim 1 , wherein any 8,14-dihydroxy-7,8-dihydrocodeinone impurity present in the oxycodone base is not converted to 14-hydroxycodeinone.

5. The method of claim 3 , wherein the crystallizing is performed at a temperature within a range of from 0° C. to 35° C.

6. The method of claim 3 , wherein the crystallizing is performed at a temperature within a range of from 5° C. to 30° C.

7. The method of claim 3 , wherein the one or more water miscible organic solvents is/are selected from the group consisting of isopropyl alcohol, ethanol, methanol, methyl ethyl ketone and acetone.

8. The method of claim 3 , wherein the purified oxycodone hydrochloride has not more than 0.001% 14-hydroxycodeinone.

9. The method of claim 3 , wherein the purified oxycodone hydrochloride has no more than 0.0005% 14-hydroxycodeinone.

10. The method of claim 1 , wherein the dissolving step is performed at a temperature within a range of from 10° C. to 40° C.

11. The method of claim 10 , wherein the dissolving step is performed at ambient temperature.

12. The method of claim 3 , wherein the crystallizing step is performed at a temperature within a range of 0° C. to 30° C.

13. The method of claim 12 , wherein the crystallizing is performed at a temperature within a range of from 5° C. to 15° C.

14. The method of claim 1 , wherein the oxycodone organic acid salt is oxycodone acetate.

15. The method of claim 3 , wherein the purified oxycodone hydrochloride has not more than 0.25% 6-α oxycodol impurity.

16. The method of claim 3 , wherein the purified oxycodone hydrochloride has not more than 0.05% of a 8,14-dihydroxy-7,8-dihydrocodeinone impurity.

17. The method of claim 14 , comprising

dissolving oxycodone base in an aqueous organic carboxylic acid solution comprised of water and acetic acid to form the oxycodone acetate salt; and

adding hydrochloric acid or ammonium chloride to the oxycodone acetate salt to form oxycodone hydrochloride.

18. The method of claim 17 , wherein the adding comprises exposing the oxycodone acetate salt to hydrochloric acid at ambient temperature to form oxycodone hydrochloride.

19. The method of claim 2 , wherein the aqueous organic acid is added in about 1 molar equivalent or less compared to moles of oxycodone base.

20. The method of claim 19 , wherein the aqueous organic acid is added in about 0.9 molar equivalents or less compared to moles of oxycodone base.

21. The method of claim 1 , wherein the dissolving the oxycodone base in the organic acid and water is performed without heating prior to introduction of hydrochloric acid.

22. The method of claim 1 , wherein the oxycodone base is dissolved without heating in acetic acid and water.

23. The method of claim 1 , comprising

at least partially dissolving oxycodone base in acetic acid and water at a temperature within a range of from 10° C. to 40° C.;

adding hydrochloric acid at ambient temperature to convert to oxycodone hydrochloride, and

adding isopropyl alcohol to precipitate the oxycodone hydrochloride, wherein the precipitated oxycodone hydrochloride has not more than 10 ppm 14-hydroxycodeinone.

24. The method of claim 23 , wherein the precipitated oxycodone hydrochloride has not more than 5 ppm 14-hydroxycodeinone.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Jul 15, 2026
From: ALTER DOMUS (US) LLC
To: CODY LABORATORIES, INC.
Reel/Frame 075270/0584 →
RELEASE OF SECURITY INTEREST Recorded Jun 30, 2026
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: CODY LABORATORIES, INC.; LANNETT COMPANY, INC.; KREMERS URBAN PHARMACEUTICALS INC.
Reel/Frame 075142/0261 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2023
From: ALTER DOMUS (US) LLC
To: LANNETT COMPANY, INC.
Reel/Frame 064088/0641 →
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2023
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: LANNETT COMPANY, INC.
Reel/Frame 064088/0663 →
SECURITY INTEREST Recorded Jun 27, 2023
From: LANNETT COMPANY, INC.; CODY LABORATORIES, INC.; KREMERS URBAN PHARMACEUTICALS INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 064088/0709 →
SECURITY INTEREST Recorded Jun 16, 2023
From: CODY LABORATORIES, INC.; LANNETT COMPANY, INC.; KREMERS URBAN PHARMACEUTICALS INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 063977/0326 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 2, 2023
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: LANNETT HOLDINGS, INC.; CODY LABORATORIES, INC.; LANNETT COMPANY, INC.
Reel/Frame 063516/0192 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - FIRST LIEN Recorded Apr 23, 2021
From: CODY LABORATORIES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 056031/0273 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT - 2ND LIEN Recorded Apr 23, 2021
From: CODY LABORATORIES, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 056031/0521 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Apr 23, 2021
From: ALTER DOMUS (US) LLC (SUCCESSOR TO MORGAN STANLEY SENIOR FUNDING, INC.)
To: KREMERS URBAN PHARMACEUTICALS INC.; CODY LABORATORIES, INC.
Reel/Frame 056031/0185 →
SECURITY INTEREST Recorded Apr 23, 2021
From: CODY LABORATORIES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 056016/0033 →
SECURITY INTEREST Recorded Dec 7, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALTER DOMUS (US) LLC, AS COLLATERAL AGENT
Reel/Frame 054566/0585 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Dec 7, 2020
From: LANNETT HOLDINGS, INC.; CODY LABORATORIES, INC.; LANNETT COMPANY, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 054627/0925 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 30, 2015
From: CODY LABORATORIES, INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 037171/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 2, 2014
From: ITOV, ZINOVY; KUZNETSOV, VLADIMIR F.; VOITSEKHOVSKI, IOURI
To: CODY LABORATORIES, INC.
Reel/Frame 031911/0488 →
Continuity (1)
Related Publication 20150166552A1 · Jun 18, 2015